Molly Henderson - 18 Jan 2024 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Role: CFO and CBO
Signature: /s/ Larry Miller, Attorney-in-Fact for Molly Henderson
Issuer symbol: PHAT
Transactions as of: 18 Jan 2024
Net transactions value: -$48,900
Form type: 4
Filing time: 22 Jan 2024, 20:22:31 UTC
Previous filing: 21 Nov 2023
Next filing: 10 Apr 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PHAT	Common Stock	Sale	$48,900	-6,307	-6%	$7.75	98,698	19 Jan 2024	Direct	F1, F2
holding	PHAT	Common Stock						1,911	18 Jan 2024	By 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PHAT	Stock Option (Right to Buy)	Award	$0	+120,000		$0.000000	120,000	18 Jan 2024	Common Stock	120,000	$7.60	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.
F2	Includes 1,944 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2024.
F3	The stock option will vest with respect to 25% of the shares of common stock on January 18, 2025, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.